Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

71.19
-1.1500-1.59%
Volume:1.97M
Turnover:141.00M
Market Cap:11.76B
PE:-29.91
High:74.16
Open:73.21
Low:70.42
Close:72.34
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:0.80
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.80%
ROA:-7.31%
PB:24.04
PE(LYR):-29.90

Loading ...

Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jan 06

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

Will FDA Approval of Tryngolza and Analyst Support Change Ionis Pharmaceuticals' (IONS) Narrative?

Simply Wall St.
·
Dec 22, 2025

Cathie Wood Dumps $11 Milllion Worth of Tesla Stock While Doubling Down on These Notable Crypto Plays

Benzinga
·
Dec 19, 2025

Ionis Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
Dec 17, 2025

RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating

MT Newswires Live
·
Dec 17, 2025

Is It Too Late to Consider Ionis After Its 126% Surge in 2025?

Simply Wall St.
·
Dec 17, 2025

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Dec 16, 2025

Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $100 From $85

THOMSON REUTERS
·
Dec 15, 2025

Ionis Pharmaceuticals (IONS): Revisiting Valuation After a Strong 1-Year Share Price Surge

Simply Wall St.
·
Dec 10, 2025

Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 10, 2025

Ionis Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $97 From $86

THOMSON REUTERS
·
Dec 09, 2025

Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares

Reuters
·
Dec 04, 2025

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news
·
Dec 03, 2025

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease

Reuters
·
Dec 02, 2025

Ionis Receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease (Axd)

THOMSON REUTERS
·
Dec 02, 2025

Ionis Pharmaceuticals Inc - on Track to Submit Nda for Zilganersen in Q1 2026

THOMSON REUTERS
·
Dec 02, 2025

Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen

Simply Wall St.
·
Dec 02, 2025

Ionis Pharmaceuticals Shares Reverse Premarket Course, Last Down 2.4%

THOMSON REUTERS
·
Dec 01, 2025

Ionis Pharmaceuticals Shares up 3.5% Premarket After Co Receives FDA Breakthrough Therapy Designation for Olezarsen for Shtg

THOMSON REUTERS
·
Dec 01, 2025